Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 5/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.34 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.33 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10109877 | 0.88 | MAPK14 (0.39) | RAB9ASMN1; SMN2GAANPC1TP53 | |
| SCHEMBL426734 | 0.85 | HCRTR1 (0.39) | RAB9ASMN1; SMN2NPC1TP53THRB | |
| SCHEMBL422736 | 0.82 | MAPK14 (0.41) | RAB9ASMN1; SMN2NPC1TP53THRB | |
| SCHEMBL421601 | 0.81 | MAPK14 (0.40) | RAB9ASMN1; SMN2GAANPC1SLC6A3 | |
| SCHEMBL14748327 | 0.80 | TSHR (0.46) | SMN1; SMN2NPC1TP53HPGDMAPT | |
| SCHEMBL14748311 | 0.80 | MAPK14 (0.34) | RAB9ASMN1; SMN2GAANPC1TP53 | |
| SCHEMBL424682 | 0.80 | PTGDR2 (0.38) | TP53MEN1KMT2ASLC6A7LMNA | |
| SCHEMBL12942141 | 0.79 | NPC1 (0.36) | RAB9ASMN1; SMN2NPC1TP53THRB | |
| SCHEMBL419496 | 0.78 | PDE4B (0.41) | RAB9ASMN1; SMN2GAANPC1TP53 | |
| SCHEMBL421762 | 0.78 | SLC5A1 (0.40) | SLC6A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546438-B2 | Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546438-B2 | Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546438-B2 | Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-10-01 | — | — | US | disclosed |
| EP-2376482-B1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO KG (DE) | 2013-03-06 | — | — | EP | disclosed |
| EP-2376482-B1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO KG (DE) | 2013-03-06 | — | — | EP | disclosed |
| US-20120022123-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022123-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022123-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| EP-2376482-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AiCuris GmbH & Co. KG (DE) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010075962-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010075962-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022123-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | TPMT, MAVS, EIF2AK2 | RAB9A 2719/4885SMN1; SMN2 377/4885GAA 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.